A 12-Week, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone/Salmeterol Multidose Dry Powder Inhaler in Adolescent and Adult Patients With Persistent Asthma Symptomatic Despite Inhaled Corticosteroid Therapy

Trial Profile

A 12-Week, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone/Salmeterol Multidose Dry Powder Inhaler in Adolescent and Adult Patients With Persistent Asthma Symptomatic Despite Inhaled Corticosteroid Therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Fluticasone propionate (Primary) ; Salmeterol/fluticasone propionate (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Sponsors Teva Branded Pharmaceutical Products R&D
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Mar 2017 Results presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 30 Jan 2017 According to a Teva Pharmaceuticals media release, the U.S. Food and Drug Administration (FDA) approved AirDuoTM RespiClick (fluticasone propionate and salmeterol inhalation powder) and ArmonAirTM RespiClick (fluticasone propionate inhalation powder) for adolescent and adult patients with asthma.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top